A novel resveratrol analog PA19 attenuates obesity‑induced cardiac and renal injury by inhibiting inflammation and inflammatory cell infiltration
Published at Rejuvenescence Science News (RSN)
Abstract
Obesity is a chronic disease induced by nutritional and metabolic disorders, and is a global health problem; 5–10% of cases are due to genetic factors, whereas 90–95% of cases arise from excessive diets and a lack of exercise (1). Obesity involves the accumulation of adipose tissue in the body and disruption of normal metabolic activities, resulting in tissue damage (2). Obesity leads to the development of a variety of conditions and disorders, including hypertension, insulin resistance, diabetes, inflammation, and obesity-induced heart and kidney injury, thereby markedly impairing human health (3–7).
An increasing number of clinical and animal studies have demonstrated the involvement of the innate immune system and inflammatory responses in the development of obesity-induced heart and kidney injury (8). Previous studies have characterized obesity-associated complications as low-grade chronic inflammatory diseases (9,10). Numerous anti-inflammatory compounds have been used in the treatment of obesity-induced tissue injury, including curcumin, berberine and resveratrol, indicating the importance of inhibiting inflammation in treating obesity-associated complications (11–13).
(1E,4E)-1-{2,4-Dimethoxy-6-[(E)-4-methoxystyryl]phenyl}-5-(2,4-dimethoxyphenyl)penta-1,4-dien-3-one (PA19) is an analog of resveratrol that was synthesized by the present research group (Fig. 1) (14). It was reported to exhibit more potent effects than resveratrol in suppressing lipopolysaccharide (LPS)-induced tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 production in mouse peritoneal macrophages (15,16). In the present study, the protective effects of PA19 on obesity-induced heart and kidney injury, and inflammation were investigated in a mouse model of obesity in vivo.
.....
F U L L T E X T : Spandidos Publications - Molecular Medicine Reports
Edited by Engadin, 23 May 2019 - 05:01 PM.